| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/11/2011 | CN101502558B Method for preparing astragalus total saponin injection from cyclodextrin composition |
| 05/11/2011 | CN101502539B Method for preparing ginkgo leaf extract cyclodextrin inclusion compound and preparation |
| 05/11/2011 | CN101491541B Thermosensitive gel type nano silver foam aerosol for women and preparation method thereof |
| 05/11/2011 | CN101468039B Method for preparing compound double-layer sustained-release medicinal membrane for treating oral mucosal disease |
| 05/11/2011 | CN101461949B Berberine cyclodextrin inclusion compound, preparation thereof and preparation method |
| 05/11/2011 | CN101444513B Cefaclor orally disintegrating tablet and preparation method thereof |
| 05/11/2011 | CN101361969B Therapeutic hepatitis b vaccine and preparation method and use thereof |
| 05/11/2011 | CN101353647B Simulating retrovirus of target tumor, and preparation and use thereof |
| 05/11/2011 | CN101327202B Vitamin K1 lyophilized powder for injection and preparation method |
| 05/11/2011 | CN101306196B Biodegradable nano-particles bonded with hemoglobin and production method thereof |
| 05/11/2011 | CN101280318B Recombinant human HNP gene liposome complex, preparation and use thereof |
| 05/11/2011 | CN101262848B Antifungal composition |
| 05/11/2011 | CN101254302B Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| 05/11/2011 | CN101234141B Total alkaloid of stephania delavayi and preparation and application thereof |
| 05/11/2011 | CN101219167B Method for preparing capsule for expelling stone |
| 05/11/2011 | CN101205302B Polyphosphate ester-polycaprolactone tri-block copolymer and uses thereof |
| 05/11/2011 | CN101190228B Compound triamcinolone acetonide acetate solution production technology |
| 05/11/2011 | CN101167736B Azithromycin microball preparation and preparation method thereof |
| 05/10/2011 | US7939683 Phospholipid-analogous compounds |
| 05/10/2011 | US7939655 Process for preparing a sterile high molecular weight hyaluronic acid formulation |
| 05/10/2011 | US7939654 Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| 05/10/2011 | US7939630 Conjugated biological molecules and their preparation |
| 05/10/2011 | US7939570 Controlled-release composition for topical application and a method of delivering an active agent to a substrate |
| 05/10/2011 | US7939562 fatty acid chain are derived from natural vegetable oils such as vernonia oil, lesquerella oil and castor oil, in which the several reactive groups such as epoxy, hydroxy and double bonds can be modified to polar and ionic groups |
| 05/10/2011 | US7939525 Conjugated psychotropic drugs and uses thereof |
| 05/10/2011 | US7939505 Amino acid lipids and uses thereof |
| 05/10/2011 | US7939502 Optimised formulation of tobramycin for aerosolization |
| 05/10/2011 | US7939494 Method for administering GLP-1 molecules |
| 05/10/2011 | US7939292 Modified heparinase III and methods of sequencing therewith |
| 05/10/2011 | US7939268 Compositions and methods for the diagnosis and treatment of tumor |
| 05/10/2011 | US7939170 Water soluble metal and semiconductor nanoparticle complexes |
| 05/10/2011 | US7939106 Surface stabilized fenofibrate particles have a particle size of 10 mu m or less; phospholipid surface modifier; dispersed in a bulking/ releasing matrix |
| 05/10/2011 | US7939105 Rapidly dispersing solid dry therapeutic dosage |
| 05/10/2011 | US7939104 Granulation; compaction; rapid dissolution upon contact with physiological solvents such as water, saliva or gastrointestinal fluids |
| 05/10/2011 | US7939099 Sustained improver of muscular fatigue |
| 05/10/2011 | US7939098 Compositions and method for transmucosal drug delivery and cryoprotection |
| 05/10/2011 | US7939094 Multiphase polymeric drug release region |
| 05/10/2011 | US7939071 Artery- and vein-specific proteins and uses therefor |
| 05/10/2011 | CA2718460A1 Compositions for intratumoral administration |
| 05/10/2011 | CA2622805C Compressed tablets comprising valsartan |
| 05/10/2011 | CA2572766C Antimicrobial compositions and wound dressings |
| 05/10/2011 | CA2503594C Positional isomers of peg ifn alpha 2a |
| 05/10/2011 | CA2485535C Modified release pharmaceutical formulation |
| 05/10/2011 | CA2477004C Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| 05/10/2011 | CA2431890C Lipid microparticles by cryogenic micronization |
| 05/10/2011 | CA2427899C Microgranules based on active principle and method for making same |
| 05/10/2011 | CA2418815C Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative |
| 05/10/2011 | CA2417806C New immunoeffector compounds |
| 05/10/2011 | CA2399866C Compositions and methods for treatment of angiogenesis in pathological lesions |
| 05/10/2011 | CA2394856C Enzyme treatment for infection |
| 05/10/2011 | CA2382560C Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 05/10/2011 | CA2379346C Conjugate for mediating cell-specific, compartment-specific or membrane-specific transport of active substances |
| 05/10/2011 | CA2375600C Method for making granules with masked taste and instant release of the active particle |
| 05/05/2011 | WO2011053618A2 Hydroxyl-terminated dendrimers |
| 05/05/2011 | WO2011053331A1 Vaccine compositions and methods of use |
| 05/05/2011 | WO2011053139A2 Aqueous composition for topical application, method of preparation, uses and device |
| 05/05/2011 | WO2011053003A2 Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer |
| 05/05/2011 | WO2011052804A1 Method of delivering agent into target cell |
| 05/05/2011 | WO2011052706A1 Dry powder inhaler of tranilast having high solubility |
| 05/05/2011 | WO2011052613A1 Cosmetic and external skin preparation, and medical instrument |
| 05/05/2011 | WO2011052500A1 Wax stable formulation |
| 05/05/2011 | WO2011052499A1 Pharmaceutical composition having improved storage stability |
| 05/05/2011 | WO2011052205A1 Polymer-coated ferrite microparticles and production method for same |
| 05/05/2011 | WO2011052089A1 Carrier materials for in vivo sustained release of drug comprising ionizing radiation-crosslinked hydrogel and method for producing same |
| 05/05/2011 | WO2011051680A1 High stability streptavidin mutant proteins |
| 05/05/2011 | WO2011051667A1 Targeted dendrimers |
| 05/05/2011 | WO2011051486A2 Pharmaceutical solution of non covalently bound albumin and acylated insulin |
| 05/05/2011 | WO2011051406A1 Sterilization of biodegradable hydrogels |
| 05/05/2011 | WO2011051354A2 Transdermal pharmaceutical compositions comprising active agents |
| 05/05/2011 | WO2011050735A1 Paclitaxel/steroidal complex |
| 05/05/2011 | WO2011050710A1 Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
| 05/05/2011 | WO2011050457A1 Stabilized formulation for oral administration of therapeutic agents and related methods |
| 05/05/2011 | WO2011039511A9 Agents, uses and methods |
| 05/05/2011 | WO2011037349A8 Target specific drug delivery system, target non-specific long-acting drug delivery system and method of controlling target specificity thereof |
| 05/05/2011 | WO2011029980A8 Therapeutic compositions for the treatment of hpv-induced diseases |
| 05/05/2011 | WO2010151353A3 Injectable beta-hairpin peptide hydrogel that kills methicillin-resistant staphylococcus aureus |
| 05/05/2011 | WO2010148007A3 Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof |
| 05/05/2011 | WO2010035122A3 Complex consisting of polysaccharide and an hpb |
| 05/05/2011 | US20110105629 Process and system for reducing sizes of emulsion droplets and emulsions having reduced droplet sizes |
| 05/05/2011 | US20110105628 Water-dispersible and multicomponent fibers from sulfopolyesters |
| 05/05/2011 | US20110105620 Organic compounds |
| 05/05/2011 | US20110105615 Tablet quickly disintegrating in the oral cavity and method for producing the same |
| 05/05/2011 | US20110105551 Analgesics for nasal administration |
| 05/05/2011 | US20110105516 Polymerized micelles |
| 05/05/2011 | US20110105449 Dry powder formulations comprising ascorbic acid derivates |
| 05/05/2011 | US20110105433 Lecithin and lc-pufa |
| 05/05/2011 | US20110105428 Hydrolysis resistant organomodified silylated ionic surfactants |
| 05/05/2011 | US20110105391 Methods and Compositions for Delivering Peptides |
| 05/05/2011 | US20110104288 Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients |
| 05/05/2011 | US20110104263 Claudin-4 binding peptides, compositions and methods of use |
| 05/05/2011 | US20110104245 Pressure-sensitive adhesives based on ethylene-vinyl acetate copolymers and adhesive resins, for medical application purposes |
| 05/05/2011 | US20110104236 Therapeutic compositions for treatment of ocular inflammatory disorders |
| 05/05/2011 | US20110104231 Bioceramic and biopolymer composite |
| 05/05/2011 | US20110104227 Absorbable polyethylene diglycolate copolymers to reduce microbial adhesion to medical devices and implants |
| 05/05/2011 | US20110104211 Compositions and methods for the therapy and diagnosis of breast cancer |
| 05/05/2011 | US20110104149 SingleC-9 Binding Agents |
| 05/05/2011 | US20110104118 Compositions and methods for therapeutic use |
| 05/05/2011 | US20110104116 Hsa-free formulations of interferon-beta |
| 05/05/2011 | US20110104111 Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles |
| 05/05/2011 | US20110104098 Isolongifolanyl-Derivatives Suitable As Odorants |